In patients with lupus nephritis, anticardiolipin antibody is more significant than anti-β2 Glycoprotein I antibody in its ability to activate complement.

Authors: Behera, Desabandhu¹, Sutar, Shashi Bhusan², Oram, Gouri³, Naik, Jitendra³

Source: European Journal of Cardiovascular Medicine. 2024, Vol. 14 Issue 2, p899-902. 4p.

Subject Terms: *ANTICARDIOLIPIN antibodies, *PHOSPHOLIPID antibodies, *BLOOD proteins, *RENAL biopsy, *IMMUNOGLOBULINS, *LUPUS nephritis

Patients with heart failure and reduced ejection fraction after sacubitril/valsartan treatment may be at risk for major adverse cardiovascular events according to ΔRDW.

Authors: Sutar, Shashi Bhusan¹, Naik, Jitendra², Oram, Gouri³, Behera, Desabandhu⁴

Source: Journal of Cardiovascular Disease Research (Journal of Cardiovascular Disease Research). 2024, Vol. 15 Issue 3, p602-608. 8p.

Subject Terms: *MAJOR adverse cardiovascular events, *ENTRESTO, *HEART failure patients, *VALSARTAN, *VENTRICULAR ejection fraction